An innovative partnership with industry will see our researchers at the Kolling Institute develop evidence-based strategies to improve osteoarthritis management in Australia and globally.
Consumer healthcare company Haleon is sponsoring a five-year fellowship to investigate the role of supplements in managing osteoarthritis and digital health technologies to improve mobility.
Osteoarthritis is a leading cause of disability, impacting more than two million Australians and 595 million people globally. It represents a significant public health burden particularly among older populations.
The fellowship will fund a postdoctoral researcher to work under the guidance of world leading osteoarthritis expert, rheumatologist and researcher Professor David Hunter. Dr Jocelyn Bowden has been awarded the fellowship and is looking forward to broadening our understanding of the use of supplements and innovative digital technologies.
Professor Hunter said the research collaboration represents a shared focus and investment in improving osteoarthritis management.
“This is a painful and disabling disease that has a huge impact on the people affected.”
“A collaborative effort between researchers and manufacturers will drive innovation and hopefully improve the lives of those affected by this disease.
“Use of supplements and natural ingredients in managing osteoarthritis is an exciting area with a lot of potential. I’m not aware of any other long-term project like this focusing on osteoarthritis.”
Dr Bincy Thampi, Medical and Scientific Affairs Lead at Haleon ANZ said they were excited to work with researchers to deliver better management strategies for the disabling disease.